1334314-19-0

1334314-19-0 structure

Name: MK-8325 dihydrochloride
Chemical Name: Methyl [(2S)-1-{(5R)-5-[7-(4-{2-[(2S)-4,4-difluoro-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}phenyl)-1H-naphtho[1,2-d]imidazol-2-yl]-3,3-dimethyl-1,3-azasilolidin-1-yl}-3-methyl-1-oxo-2-butanyl]carbamate dihydrochloride
CAS Number: 1334314-19-0
Molecular Formula: C₄₃H₅₄Cl₂F₂N₈O₆Si
Molecular Weight: 915.927
Create Date: 2020-01-11 17:49:49
Modify Date: 2024-01-18 21:57:45
MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively; also demonstrates potencies comparable to MK-4882 against a panel of mutants in both the GT1a and GT1b backgrounds (GT1a M28V IC50=0.1 nM); demonstrates no cell toxicity with a CC50 >25 uM against Huh-7 replicon cells. HCV Infection Phase 1 Clinical

Name	Methyl [(2S)-1-{(5R)-5-[7-(4-{2-[(2S)-4,4-difluoro-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}phenyl)-1H-naphtho[1,2-d]imidazol-2-yl]-3,3-dimethyl-1,3-azasilolidin-1-yl}-3-methyl-1-oxo-2-butanyl]carbamate dihydrochloride
Synonyms	Carbamic acid, N-[(1S)-1-[[(2S)-4,4-difluoro-2-[4-[4-[2-[(5R)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-3,3-dimethyl-1-aza-3-silacyclopent-5-yl]-1H-naphth[1,2-d]imidazol-7-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester, hydrochloride (1:2) Methyl [(2S)-1-{(5R)-5-[7-(4-{2-[(2S)-4,4-difluoro-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}phenyl)-1H-naphtho[1,2-d]imidazol-2-yl]-3,3-dimethyl-1,3-azasilolidin-1-yl}-3-methyl-1-oxo-2-butanyl]carbamate dihydrochloride

Description	MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively; also demonstrates potencies comparable to MK-4882 against a panel of mutants in both the GT1a and GT1b backgrounds (GT1a M28V IC50=0.1 nM); demonstrates no cell toxicity with a CC50 >25 uM against Huh-7 replicon cells. HCV Infection Phase 1 Clinical
References	References 1. Nair AG, et al. Bioorg Med Chem Lett. 2018 Mar 20. pii: S0960-894X(18)30242-7. View Related Products by Target HCV HCV Infection